Skip to main content

lung cancer Archives

Effort seeks to enroll more Black patients in lung cancer trials

Mar. 25, 2021—Researchers from Vanderbilt University Medical Center are part of a multi-institutional study that aims to improve participation in lung cancer clinical trials among Black patients from Southern states.

Read more


Vanderbilt research played key role in new lung screen guidelines

Mar. 18, 2021—The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.

Read more


EGFR Resisters/LUNGevity fund lung cancer research

Mar. 18, 2021—Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.

Read more


Study incorporates genetics with smoking history to identify high-risk smokers for lung cancer screening

Mar. 9, 2021—A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening.

Read more


Gift in memory of Phran Galante boosts lung cancer research

Feb. 25, 2021—A gift in memory of music industry executive and community philanthropist Phran Galante will support the work of Christine Lovly, MD, PhD, associate professor of Medicine and Ingram Professor of Cancer Research, to improve targeted therapies for lung cancer.

Read more


New therapeutic target for lung cancer

Nov. 12, 2020—Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer.

Read more


Newer targeted therapy prolongs life for lung cancer patients

Aug. 13, 2020—Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase 3 study.

Read more


Iams honored by National Comprehensive Cancer Network

Jul. 30, 2020—Wade Iams, MD, MSCI, assistant professor of Medicine, is the recipient of a National Comprehensive Cancer Network Foundation Young Investigator Award.

Read more


Criteria for lung cancer screens may be expanded

Jul. 23, 2020—The U.S. Preventive Services Task Force (USPSTF) is recommending two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.

Read more


ASCO press program highlights COVID-19 outcomes in lung cancer patients

May. 26, 2020—People with thoracic cancers sickened by COVID-19 were especially vulnerable to deaths with a 35% mortality rate, according to early results from TERAVOLT, a global consortium that tracks outcomes among this vulnerable patient population.

Read more


Study finds AI can categorize cancer risk of lung nodules

May. 7, 2020—by Tom Wilemon Computed tomography scans for people at risk for lung cancer lead to earlier diagnoses and improve survival rates, but they can also lead to overtreatment when suspicious nodules turn out to be benign. A study published in American Journal of Respiratory and Critical Care Medicine indicates that an artificial intelligence strategy can correctly assess and categorize these indeterminate pulmonary nodules (IPNs). When compared to the conventional risk models clinicians currently use, the algorithm developed by the team of researchers in a very large dataset (15,693 nodules) reclassified IPNs into low-risk or high-risk categories in over a third of cancers and benign nodules. “These results suggest the potential clinical utility of this deep learning algorithm to revise the probability of cancer among IPNs aiming to decrease invasive procedures and shorten time to diagnosis,” said Pierre Massion, MD, Cornelius Vanderbilt Chair in Medicine at Vanderbilt University, the study’s lead author. Currently, clinicians refer to guidelines issued by the American College of Radiology and the American College of Chest Physicians. Adherence to these guidelines can be variable, and how patient cases are classified can be subjective. With the goal of providing clinicians with an unbiased assessment tool, the researchers developed an algorithm based on datasets from the National Lung Screening Trial, Vanderbilt University Medical Center and Oxford University Hospital. Their study is the first to validate a risk stratification tool on multiple independent cohorts and to show reclassification performance that is significantly superior to existing risk models. With IPNs, clinicians are often faced with the dilemma of weighing whether to advise a patient to undergo an invasive surgical procedure, which may be unnecessary, against a watch-and-wait strategy, which may result in delaying needed cancer treatment. A definitive diagnosis of an IPN can take up to two years. Better assessment tools are needed by clinicians as screenings for patients at risk for lung cancer increase. Lung cancer is the leading cause of cancer-related death in the United States and globally. The overall five-year survival rate is 21.7%, but it is much greater (92%) for those patients who receive an early diagnosis of stage IA1 non-small cell cancer. n

Read more


Study tracks genomics of lung tumor behavior

Apr. 9, 2020—A study by Vanderbilt researchers has identified genomic alterations in early stage adenocarcinomas of the lung that may indicate whether the lesions develop into aggressive tumors.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more